Skip to main content

Table 2 Biomolecular alterations and ORR, PFS and OS: univariate analysis

From: Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study

 

n

ORR %

Median PFS (months)

(95% CI)

p

Median OS (months)

(95% CI)

p

Overall

67

 

4.3 (2.9-5.5)

-

9.2 (7.3-12.0)

-

KRAS

      

WT

53

30.2

5.2 (3.4-6.7)

 

8.7 (6.9-14.6)

 

Mut

14

7.1

2.7 (2.2-3.9)

0.070

9.4 (6.0-12.0)

0.114

BRAF

      

WT

55

29.1

5.1 (3.2-6.7)

 

9.6 (8.3-13.9)

 

Mut

12

8.3

2.8 (1.4-3.9)

0.005

5.8 (2.1-8.4)

0.008

PIK3CA

      

WT

58

27.6

5.1 (3.4-6.2)

 

9.9 (8.3-13.7)

 

Mut

9

11.1

2.3 (2.1-3.3)

0.031

6.6 (4.4-7.3)

0.013

PTEN

      

<5%

40

22.5

3.3 (2.3-5.2)

 

8.3 (6.0-12.4)

 

≥5%

27

29.6

6.2 (4.0-8.7)

0.073

11.0 (8.0-14.6)

0.647